Literature DB >> 10517605

Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum.

Isabelle Guillemin1, Wladimir Sougakoff1, Emmanuelle Cambau1, Valérie Revel-Viravau1, Nicole Moreau2, Vincent Jarlier1.   

Abstract

The DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum, which are species naturally resistant, moderately susceptible and susceptible to fluoroquinolones, respectively, were purified by affinity chromatography on novobiocin-Sepharose columns. The DNA gyrase inhibiting activities (IC50 values) of classical quinolones and fluoroquinolones were determined from the purified enzymes and were compared to the corresponding antibacterial activities (MICs). Regarding M. fortuitum bv. peregrinum, which is nearly as susceptible as Escherichia coli, the corresponding MIC and IC50 values of quinolones were significantly lower than those found for M. avium and M. smegmatis (e.g. for ofloxacin, MICs of 0.25 versus 32 and 1 microg ml(-1), and IC50 values of 1 versus 8 and 6 microg ml(-1), respectively). Such a result could be related to the presence of Ser-83 in the quinolone-resistance-determining region of the gyrase A subunit of M. fortuitum bv. peregrinum, as found in wild-type E. coli, instead of Ala-83 in M. avium and M. smegmatis, as found in fluoroquinolone-resistant E. coli mutants. The IC50 values of quinolones against the M. avium and M. smegmatis DNA gyrases were similar, while the corresponding MICs were 32-fold higher for M. avium when compared to M. smegmatis, suggesting that an additional mechanism, such as a low cell wall permeability or a drug efflux, could contribute to the low antibacterial potency of quinolones against M. avium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517605     DOI: 10.1099/00221287-145-9-2527

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  10 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

Authors:  T Lu; X Zhao; X Li; A Drlica-Wagner; J Y Wang; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm.

Authors:  F Masselot; A Boulos; M Maurin; J M Rolain; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.

Authors:  Muhammad Malik; Kevin R Marks; Arkady Mustaev; Xilin Zhao; Kalyan Chavda; Robert J Kerns; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

7.  Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.

Authors:  Stéphanie Matrat; Alexandra Aubry; Claudine Mayer; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

8.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

9.  The challenge of intracellular antibiotic accumulation, a function of fluoroquinolone influx versus bacterial efflux.

Authors:  Julia Vergalli; Alessio Atzori; Jean-Marie Pagès; Jelena Pajovic; Estelle Dumont; Giuliano Malloci; Muriel Masi; Attilio Vittorio Vargiu; Mathias Winterhalter; Matthieu Réfrégiers; Paolo Ruggerone
Journal:  Commun Biol       Date:  2020-04-28

10.  The role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance.

Authors:  Jansy Passiflora Sarathy; Véronique Dartois; Edmund Jon Deoon Lee
Journal:  Pharmaceuticals (Basel)       Date:  2012-11-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.